Table 2.
ASCO, American Society of Clinical Oncology; EGTM, European Group on Tumor Markers; ER+, Estrogen-receptor-positive; ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network; DBCG, Danish Breast Cancer Group; CCTG, Canadian Cancer Trials Group.
| Oncotype DX (21-gene assay) | MammaPrint(70-gene assay) | Prosigna(50-gene assay) | EndoPredict (12-gene assay) | Breast Cancer Index(7-gene assay) | |
|---|---|---|---|---|---|
| Studies Used for Development | NSABP-14 NSABP B-20 (5) |
Netherlands Cancer Institute Cohort (144), RASTER study (52) | British Columbia Breast Cancer cohort (95) | GEICAM trial (105), ABCSG-6 (107), ABCSG-8 (98) |
ATAC trial (96), Stockholm (111) |
| Retrospective Studies | NSABP B-20 (5) SWOG-8814 (26), (TransATAC (22), SEER 18 (145), WSG-ADAPT (38) |
Pooled database of 7 prospective trials (144) | ATAC (96), ABCSG-8 (98), DBCG (100) | ABCSG-6 (107), ABCSG-8 (98) | Stockholm (111), TransATAC (22), CCTG, MA.17 (112), aTTOM trial (120) |
| Prospective Studies | TAILORx, RxPONDER. | MINDACT, PROMIS | OPTIMA | NA | NA |
| Prognostic/Predictive | Yes for both, 10-year RR and adjuvant chemotherapy benefit | Only Prognostic, 10-year RR | Yes for both, 10-year RR and late recurrence (>5 years) for patients HR+ve and LN-ve disease | Only prognostic, 10-year RR | Yes for both, 10-year RR and late recurrence (>5 years) extended adjuvant endocrine therapy benefit |
| Recommendations | NCCN, ASCO, ESMO, St. Gallen, AJCC, NICE, EGTM | NCCN*, ASCO, ESMO, St. Gallen, EGTM | NCCN*, ASCO, ESMO, St. Gallen, EGTM | ASCO, ESMO, St. Gallen, EGTM | ASCO, St. Gallen, EGTM |
NCNN* discussed but not specifically recommended.